Asher D. Schachter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Asher D. Schachter has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
J. A. Palmer
1 shared publicationJ. Baluarte
1 shared publicationK. E. Meyers
1 shared publicationK. L. Brayman
1 shared publicationL. D. Spaneas
1 shared publicationM. Salmanullah
1 shared publication
Latest Publications
- 26 March 2004
- Published by Wiley in Pediatric Transplantation
- Vol. 8 (2) , 171-177
Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocol
Abstract: Immunosuppression with SRL may provide an opportunity to avoid long‐term exposure to the nephrotoxicity of CNI. Thus, we have initiated an experimental protocol of IL‐2r antibody induction, prednisone, MMF and SRL in pediatric renal transplant recipients (median age 15.5 yr, IQR 8.5, range 1.3–21.7). The recipients were treated with daclizumab every 2 wk for the first 2 months, prednisone on a tapering schedule, MMF at 1200 mg/m2/day and SRL given b.i.d. The SRL was dosed to achieve defined target whole blood 12‐h trough levels. We performed 24 SRL PK profiles in 13 stable pediatric renal transplant recipients at 1 and 3 months post‐transplant. Half‐life (T1/2) and terminal T1/2 were 9.7 (7.1–24.6) and 10.8 (4.4–95.2) hours (median, range) respectively at month 1, and were 9.6 (5–17.8) and 12.1 (4.7–71.0) hours respectively at month 3. SRL trough levels correlated with AUC (r2 = 0.84, p < 0.001). There was no relationship between SRL and mycophenolic acid (MPA) AUC values (r2 = 0.04). During the first 3 months post‐transplant only one patient experienced severe neutropenia and another patient had subclinical (histologic) evidence of a mild acute rejection episode with no change in renal function. We conclude that the T1/2 of SRL in pediatric renal transplant recipients not treated with CNI is much shorter than what has been reported for adults, due to rapid metabolism. We conclude that children require SRL dosing every 12 h, higher doses and frequent drug monitoring to achieve target SRL concentrations.
- 26 March 2004
- Published by Wiley in Pediatric Transplantation
- Vol. 8 (2) , 171-177
Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocol
Abstract: Immunosuppression with SRL may provide an opportunity to avoid long‐term exposure to the nephrotoxicity of CNI. Thus, we have initiated an experimental protocol of IL‐2r antibody induction, prednisone, MMF and SRL in pediatric renal transplant recipients (median age 15.5 yr, IQR 8.5, range 1.3–21.7). The recipients were treated with daclizumab every 2 wk for the first 2 months, prednisone on a tapering schedule, MMF at 1200 mg/m2/day and SRL given b.i.d. The SRL was dosed to achieve defined target whole blood 12‐h trough levels. We performed 24 SRL PK profiles in 13 stable pediatric renal transplant recipients at 1 and 3 months post‐transplant. Half‐life (T1/2) and terminal T1/2 were 9.7 (7.1–24.6) and 10.8 (4.4–95.2) hours (median, range) respectively at month 1, and were 9.6 (5–17.8) and 12.1 (4.7–71.0) hours respectively at month 3. SRL trough levels correlated with AUC (r2 = 0.84, p < 0.001). There was no relationship between SRL and mycophenolic acid (MPA) AUC values (r2 = 0.04). During the first 3 months post‐transplant only one patient experienced severe neutropenia and another patient had subclinical (histologic) evidence of a mild acute rejection episode with no change in renal function. We conclude that the T1/2 of SRL in pediatric renal transplant recipients not treated with CNI is much shorter than what has been reported for adults, due to rapid metabolism. We conclude that children require SRL dosing every 12 h, higher doses and frequent drug monitoring to achieve target SRL concentrations.
- 1 December 2001
- Published by Wiley in Pediatric Transplantation
- Vol. 5 (6) , 406-409
Single‐center analysis of early recurrence of nephrotic syndrome following renal transplantation in children
Recurrence of nephrotic syndrome (NS) after transplantation (Tx) occurs in 20–50% of renal transplant recipients, with a median time to recurrence of 14 days and a 50% rate of graft loss. We performed a retrospective analysis of 22 pediatric patients with NS who received renal transplants at the Children's Hospital, Boston, between 1982 and 1999. During the first 14 days following Tx, 13 (59%) patients developed clinical recurrent nephrotic syndrome (RNS). RNS developed in 50% of living donor recipients and in 70% of cadaveric donor recipients (p= non‐significant). Seven of the 13 patients with RNS were treated with plasmapheresis, while six received standard immunosuppressive induction therapy only. Two of the seven treated patients and one of the six untreated patients lost their grafts to RNS, yielding a total RNS graft loss rate of 23%. However, patients with RNS who achieved remission had significantly higher cumulative graft survival at 5 yr than did RNS patients who did not achieve remission (p< 0.001). Overall cumulative graft survival at 5 yr was not significantly different between the two groups: 67% in those with non‐recurrent nephrotic syndrome (NRNS) vs. 64% in those with RNS, p= non‐significant. We conclude that successful reversal of early RNS improves long‐term graft survival in pediatric RNS. Multi‐center studies are sorely needed to develop novel, less toxic therapies for native and recurrent NS.
- 1 December 2001
- Published by Wiley in Pediatric Transplantation
- Vol. 5 (6) , 406-409
Single‐center analysis of early recurrence of nephrotic syndrome following renal transplantation in children
Recurrence of nephrotic syndrome (NS) after transplantation (Tx) occurs in 20–50% of renal transplant recipients, with a median time to recurrence of 14 days and a 50% rate of graft loss. We performed a retrospective analysis of 22 pediatric patients with NS who received renal transplants at the Children's Hospital, Boston, between 1982 and 1999. During the first 14 days following Tx, 13 (59%) patients developed clinical recurrent nephrotic syndrome (RNS). RNS developed in 50% of living donor recipients and in 70% of cadaveric donor recipients (p= non‐significant). Seven of the 13 patients with RNS were treated with plasmapheresis, while six received standard immunosuppressive induction therapy only. Two of the seven treated patients and one of the six untreated patients lost their grafts to RNS, yielding a total RNS graft loss rate of 23%. However, patients with RNS who achieved remission had significantly higher cumulative graft survival at 5 yr than did RNS patients who did not achieve remission (p< 0.001). Overall cumulative graft survival at 5 yr was not significantly different between the two groups: 67% in those with non‐recurrent nephrotic syndrome (NRNS) vs. 64% in those with RNS, p= non‐significant. We conclude that successful reversal of early RNS improves long‐term graft survival in pediatric RNS. Multi‐center studies are sorely needed to develop novel, less toxic therapies for native and recurrent NS.